• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LIANG Jinlai, XU Wei, YIN Tingjie, HUO Meirong. Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve[J]. Journal of China Pharmaceutical University, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301
Citation: LIANG Jinlai, XU Wei, YIN Tingjie, HUO Meirong. Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve[J]. Journal of China Pharmaceutical University, 2018, 49(3): 255-262. DOI: 10.11665/j.issn.1000-5048.20180301
shu

Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve

More Information
    Graphical Abstract
    • Abstract
  • Hypoxia, a salient feature of solid tumors, is often associated with invasiveness, metastasis and resistance to anticancer drugs. The strategies including the use of oxygen-carriers based on hyperbaric oxygen and blood substitutes to transport oxygen into tumors or in situ generation of O2 from the tumor microenvironment endogenous H2O2 have been explored to relieve the tumor hypoxia and to improve therapeutic efficiency. In addition, it is potential to design hypoxia-responsive nanocarriers based on tumor hypoxia microenvironment to deliver anticancer drugs to the targeted tumor site, thereby improve drug concentrations in targeted site, significantly increase the antitumor efficiency and reduce the side-effects of drugs. This review gives an overview of the advances in relieving tumor hypoxia and hypoxia-responsive nanocarriers for tumor to provide a reference for the research and development of new antitumor drugs.
    • FullText(HTML)
    • References (47)
  • [1]
    Alimoradi H,Matikonda SS,Gamble AB,et al.Hypoxia responsive drug delivery systems in tumor therapy[J].Curr Pharm Des,2016,22(19):2808-2820.
    [2]
    Rapisarda A,Melillo G.Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies[J].Drug Resist Updat,2009,12(3):74-80.
    [3]
    Bryant JL,Meredith SL,Williams KJ,et al.Targeting hypoxia in the treatment of small cell lung cancer[J].Lung Cancer,2014,86(2):126-32.
    [4]
    Du J,Lane LA,Nie S.Stimuli-responsive nanoparticles for targeting the tumor microenvironment[J].J Control Release,2015,219:205-214.
    [5]
    Khawar IA,Kim JH,Kuh HJ.Improving drug delivery to solid tumors:priming the tumor microenvironment[J].J Control Release,2015,201:78-89.
    [6]
    Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer—a review[J].Target Oncol,2012,7(4):233-242.
    [7]
    Alam F,Yadav N,Ahmad M,et al.Blood substitutes:possibilities with nanotechnology[J].Indian J Hematol Blood Transfus,2014,30(3):155-162.
    [8]
    Spahn DR.Blood substitutes.Artificial oxygen carriers:perfluorocarbon emulsions[J].Crit Care,1999,3(5):R93-97.
    [9]
    Greenburg AG,Kim HW.Hemoglobin-based oxygen carriers[J].Crit Care,2004,8(Suppl 2):S61-S64.
    [10]
    Yuan J,Cen Y,Kong XJ,et al.MnO2-nanosheet-modified upconversion nanosystem for sensitive turn-on fluorescence detection of H2O2 and glucose in blood[J].ACS Appl Mater Interfaces,2015,7(19):10548-10555.
    [11]
    Fan W, Bu W, Shen B, et al. Intelligent MnO2 nanosheets anchored with upconversionnanoprobes for concurrent pH-/H2O2-responsive UCL imaging and oxygen-elevated synergetic therapy[J].Adv Mater,2015,27(28):4155-4161.
    [12]
    Stępień K, Ostrowski RP, Matyja E. Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies,including brain tumours[J].Med Oncol,2016,33(9):101.
    [13]
    Peng HS,Liao MB,Zhang MY,et al.Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells[J].PLoS One,2014,9(6):e100814.
    [14]
    Lu Z, Ma J, Liu B, et al. Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice[J].Cancer Med,2016,5(11):3147-3155.
    [15]
    Hartmann KA,van der Kleij AJ,Carl UM,et al.Effects of hyperbaric oxygen and normobaric carbogen on the radiation response of the rat rhabdomyosarcoma R1H[J].Int J Radiat Oncol Biol Phys,2001,51(4):1037-1044.
    [16]
    Wu W,Yang Q,Li T,et al.Hemoglobin-based oxygen carriers combined with anticancer drugs may enhance sensitivity of radiotherapy and chemotherapy to solid tumors[J].Artif Cells Blood Substit Immobil Biotechnol,2009,37(4):163-165.
    [17]
    Vásquez DM,Ortiz D,Alvarez OA,et al.Hemorheological implications of perfluorocarbon based oxygen carrier interaction with colloid plasma expanders and blood[J].Biotechnol Prog,2013,29(3):796-807.
    [18]
    Riess JG.Perfluorocarbon-based oxygen delivery[J].Artif Cells Blood Substit Immobil Biotechnol,2006,34(6):567-580.
    [19]
    Li F,Mei H,Gao Y,et al.Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer[J].Biomaterials,2017,145:56-71.
    [20]
    Luo Z,Zheng M,Zhao P,et al.Self-monitoring artificial red cells with sufficient oxygen supply for enhanced photodynamic therapy[J].Sci Rep,2016,6:23393.
    [21]
    Cheng Y,Cheng H,Jiang C,et al.Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy[J].Nat Commun,2015,6:8785.
    [22]
    Song X,Feng L,Liang C,et al.Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies[J].Nano Lett,2016,16(10):6145-6153.
    [23]
    Zhang L,Li J,Zong L,et al.Reactive oxygen species and targeted therapy for pancreatic cancer[J].Oxid Med Cell Longev,2016,2016(3):1616781.
    [24]
    Vilema-Enríquez G,Arroyo A,Grijalva M,et al.Molecular and cellular effects of hydrogen peroxide on human lung cancer cells:potential therapeutic implications[J].Oxid Med Cell Longev,2016,2016(6):1-12.
    [25]
    Lennicke C,Rahn J,Lichtenfels R,et al.Hydrogen peroxide-production,fate and role in redox signaling of tumor cells[J].Cell Commun Signal,2015,13:39.
    [26]
    Chen Q, Chen J, Liang C, et al. Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration,hypoxia relieve,and synergistic combination therapy[J].J Control Release,2017,263:79-89.
    [27]
    Prasad P,Gordijo CR,Abbasi AZ,et al.Multifunctional albumin-MnO2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia,acidosis,vascular endothelial growth factor and enhance radiation response[J].ACS Nano,2014,8(4):3202-3212.
    [28]
    Chen H,He W,Guo Z.An H2O2-responsive nanocarrier for dual-release of platinum anticancer drugs and O2:controlled release and enhanced cytotoxicity against cisplatin resistant cancer cells[J].Chem Commun(Camb),2014,50(68):9714-9717.
    [29]
    Chen H,Tian J,He W,et al.H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells[J].J Am Chem Soc,2015,137(4):1539-1547.
    [30]
    Song G,Chen Y,Liang C,et al.Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy[J].Adv Mater,2016,28(33):7143-7148.
    [31]
    Zhu W,Dong Z,Fu T,et al.Modulation of hypoxia in solid tumor microenvironment with MnO2 nanoparticles to enhance photodynamic therapy[J].Adv Funct Mater,2016,26(30):5490-5498.
    [32]
    Gao S,Wang G,Qin Z,et al.Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy[J].Biomaterials,2017,112:324-335.
    [33]
    Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs[J].Cancer Chemother Pharmacol,2016,77(3):441-457.
    [34]
    Guise CP,Mowday AM,Ashoorzadeh A,et al.Bioreductive prodrugs as cancer therapeutics:targeting tumor hypoxia[J].Chin J Cancer,2014,33(2):80-86.
    [35]
    Denny WA.Hypoxia-activated prodrugs in cancer therapy:progress to the clinic[J].Future Oncol,2010,6(3):419-428.
    [36]
    Denny WA,Wilson WR,Hay MP.Recent developments in the design of bioreductive drugs[J].Br J Cancer Suppl,1996,27:S32-S38.
    [37]
    Mistry IN, Thomas M, Calder EDD, et al. Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy[J].Int J Radiat OncolBiol Phys,2017,98(5):1183-1196.
    [38]
    Feng L, Cheng L, Dong Z, et al. Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy[J].ACS Nano,2017,11(1):927-937.
    [39]
    Li SY, Cheng H, Qiu WX, et al. Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy[J].Biomaterials,2017,142:149-161.
    [40]
    Wang Y,Xie Y,Li J,et al.Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy[J].ACS Nano,2017,11(2):2227-2238.
    [41]
    Thambi T,Park JH,Lee DS.Hypoxia-responsive nanocarriers for cancer imaging and therapy:recent approaches and future perspectives[J].Chem Commun(Camb),2016,52(55):8492-8500.
    [42]
    Thambi T,Deepagan VG,Yoon HY,et al.Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery[J].Biomaterials,2014,35(5):1735-1743.
    [43]
    Kang L,Fan B,Sun P,et al.An effective tumor-targeting strategy utilizing hypoxia-sensitive siRNA delivery system for improved anti-tumor outcome[J].Acta Biomater,2016,44:341-354.
    [44]
    Ahmad Z,Lv S,Tang Z,et al.Methoxy poly(ethylene glycol)-block-poly(glutamic acid)-graft-6-(2-nitroimidazole)hexyl amine nanoparticles for potential hypoxia-responsive delivery of doxorubicin[J].J Biomater Sci Polym Ed,2016,27(1):40-54.
    [45]
    Liu H,Zhang R,Niu Y,et al.Development of hypoxia-triggered prodrug micelles as doxorubicin carriers for tumor therapy[J].RSC Adv,2015,5(27):20848-20857.
    [46]
    Perche F,Biswas S,Wang T,et al.Hypoxia-targeted siRNA delivery[J].Angew Chem Int Ed Engl,2014,53(13):3362-3366.
    [47]
    Kulkarni P,Haldar MK,You S,et al.Hypoxia-responsive polymersomes for drug delivery to hypoxic pancreatic cancer cells[J].Biomacromolecules,2016,17(8):2507-2513.
    • Related Articles

  • Related Articles

    [1]HUANG Shuzhen, WANG Guangji, XIE Yuan. Advances in molecular mechanisms of organelle interaction and their role in disease development[J]. Journal of China Pharmaceutical University, 2019, 50(4): 389-396. DOI: 10.11665/j.issn.1000-5048.20190402
    [2]ZHENG Mei, LIU Fulei, XUE Jingwei, LIU Wenyuan. Investigation of herb-drug interaction between Liuwei Dihuang Pills and nifedipine based on rat liver microsomes and HPLC fingerprints[J]. Journal of China Pharmaceutical University, 2018, 49(2): 195-201. DOI: 10.11665/j.issn.1000-5048.20180209
    [3]ZHANG Tianxing, HUANG Wei, HUANG Xueyu, LIAO Anping. Interaction of oleanolic acid and its derivatives with bovine serum albumin by spectrofluorimetry[J]. Journal of China Pharmaceutical University, 2017, 48(5): 572-576. DOI: 10.11665/j.issn.1000-5048.20170511
    [4]WANG Yuhao, ZHANG Xue, ZHOU Xiaoting, HE Hua, LIU Xiaoquan. Pharmacokinetic interaction between sunitinib and ramipril in rats[J]. Journal of China Pharmaceutical University, 2017, 48(1): 60-65. DOI: 10.11665/j.issn.1000-5048.20170109
    [5]ZENG Yu, JI Yibing. Study of interaction between bovine serum albumin and nefopam enantiomers with affinity capillary monolith[J]. Journal of China Pharmaceutical University, 2016, 47(1): 66-72. DOI: 10.11665/j.issn.1000-5048.20160109
    [6]CHEN Lei, YANG Ping, JI Yibing. Chiral separation of esomeprazole and its enantiomer by affinity capillary electrophoresis[J]. Journal of China Pharmaceutical University, 2014, 45(4): 444-449. DOI: 10.11665/j.issn.1000-5048.20140411
    [7]CHENG Yu, HE Hua, CHEN Yuan-cheng, HUANG Li-hua, SI Qian, LIU Xiao-quan. Effects of content variation of water-soluble components in Dansheninjection on homocysteine metabolism in rats[J]. Journal of China Pharmaceutical University, 2011, 42(3): 255-261.
    [8]Interactions of folic acid and deoxycholic acid with bovine serum albumin as well as the effects of coexisting paclitaxel[J]. Journal of China Pharmaceutical University, 2010, 41(3): 253-258.
    [9]Metabolic Interaction of Cinildipine with Some Co-administrated Drugs in Human Liver Microsomes[J]. Journal of China Pharmaceutical University, 2004, (6): 43-46.
    [10]Studies on the Reaction Between Levofloxacin and Bovine Serum Albumin[J]. Journal of China Pharmaceutical University, 2004, (5): 70-73.

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365747

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return